1. The Defendants jointly share KRW 207,223,535 to Plaintiff A, KRW 3,00,000 to Plaintiff B, and KRW 2,00,000 to Plaintiff C, and the above.

1. Basic facts

A. The Plaintiffs’ related Plaintiff B is an oriental medical doctor with the husband of the Plaintiff, and the Plaintiff A gave birth to the Plaintiff Friend C.

B. On September 14, 2011, 201, 1207, 1207, 1207, 2007, 2007, 2007, 2007, 2007, 2007, 2007, 2007, 2007, 2007, 2007, 2007, 2007, 207, 2007, 207, 2007, 207, 207, 207, 207, 207, 207, 207, 207, 207, 207, 207, 207, 207, 207, 2007, 207, 2007, 207).

3) As the above herb drugs purchased from Defendant E were used, G was Defendant D Co., Ltd. (hereinafter “D”) on September 23, 201 and September 30, 2011.

(B) From the perspective of the foregoing, the pharmaceutical products in question were additionally purchased, and on October 10, 201, the pharmaceutical products were manufactured in accordance with the medicinal medicine prescription of Plaintiff B and sent to Plaintiff A as a selective distribution (hereinafter referred to as “the pharmaceutical products in question”), using the pharmaceutical products. The pharmaceutical products produced by G were collectively referred to as “the pharmaceutical products in question”

). 다. 피고들이 공급한 한약재의 신독성(腎毒性, nephrotoxicity)성분 함유 1) 약사법 제52조에 따라 식품의약품안전청장이 고시한 대한약전외한약(생약)규격집(2011. 3. 22. 고시 제2011-12호로 개정된 것, 이하 ‘생약규격집’이라 한다)에는 한약재(생약)로서의 ‘통초’에 대하여 통탈목 Tetrapanax papyriferus

K. Koch (두릅나무과 Araliaceae)]의 줄기의 수(髓 로, 그 성상은 '원주형의 수부로 길이 3 ~ 6 cm, 지름 12 ~ 30 mm이다.

Colors are fluored, fluored, fluored and shot.